Liquidia (LQDA) Stock Tumbles 57% Following Patent Infringement Verdict

Key Takeaways

Table of Contents

Liquidia (LQDA) shares plummeted 57% following an adverse patent infringement decision.
A federal judge in Delaware determined that Yutrepia violates a United Therapeutics patent.
Shares of United Therapeutics (UTHR) surged 12% following the announcement.
Share volume exploded to 22.95 million, approximately 19 times normal levels.
Liquidia intends to pursue appeals and request FDA label modifications for Yutrepia.

Shares of Liquidia (LQDA) experienced a devastating 57% decline during Wednesday’s trading session, settling at $30.26. In after-hours trading, the stock edged marginally higher by 0.13% to reach $30.30.

Liquidia Corporation, LQDA

The dramatic selloff came after a Delaware federal court decision determined that Yutrepia, Liquidia’s pulmonary treatment, violates intellectual property rights held by competitor United Therapeutics (UTHR).

The judge validated two specific claims from United Therapeutics’ patent portfolio and found them infringed. Additional claims brought forward in the litigation were deemed invalid.

The patent in question protects treatment protocols for pulmonary hypertension associated with interstitial lung disease (PH-ILD). It encompasses inhaled treprostinil administered via dry powder systems—the exact delivery mechanism used by Yutrepia.

Implications of the Court Decision for Yutrepia

The court additionally rejected Liquidia’s attempt to exclude certain evidence related to United Therapeutics’ patent ownership. The presiding judge determined that Liquidia received adequate advance notification and failed to raise timely objections.

Liquidia acknowledged it cannot currently quantify the financial impact of this ruling. The ultimate consequences hinge on the appeals process and subsequent legal developments.

Potential outcomes range from eliminating the PH-ILD indication from Yutrepia’s approved uses to implementing stricter distribution controls. United Therapeutics has petitioned for an injunction that would constrain Yutrepia’s market access.

Each party must present proposed judgments to the court within seven days. A final determination is anticipated shortly thereafter.

Liquidia Chief Executive Roger Jeffs expressed strong disagreement with the verdict. “We respectfully disagree with the Court’s decision regarding claims 1 and 14 and are fully prepared to pursue all available appellate options,” he stated.

Jeffs revealed that Liquidia will submit a supplemental filing to the FDA requesting removal of the PH-ILD indication from Yutrepia’s approved label.

Yutrepia received regulatory clearance in 2025 for treating both pulmonary arterial hypertension and PH-ILD. The PH-ILD designation now faces legal uncertainty.

Analyst Perspectives on the Verdict

Market analysts offered mixed assessments of the ruling’s severity. Raymond James analyst Ryan Deschner characterized the rejected evidence motion as unfavorable for Liquidia’s overall legal position.

Leerink Partners interpreted the outcome as favorable to United Therapeutics, noting the court validated both patent enforceability and infringement. RBC Capital’s Lisa Walter suggested the decision creates significant obstacles for Yutrepia’s competitive prospects.

United Therapeutics shares rallied 12% to $540.54 in response to the verdict. The ruling strengthens intellectual property protections surrounding its flagship inhaled therapy, Tyvaso.

Liquidia’s stock reached its lowest level in nearly four months following the announcement. The decline represents approximately $3.18 billion in erased market capitalization.

Trading intensity surged dramatically around the news. Volume touched 22.95 million shares, nearly 19 times the typical daily average of 1.21 million.

Liquidia’s Relative Strength Index currently registers at 20.23, a threshold generally indicating oversold conditions. The stock now trades at approximately 12% of its 52-week price range.

Notwithstanding Wednesday’s collapse, Liquidia shares remain 33% higher compared to twelve months ago. The company’s market capitalization now stands at $2.71 billion, down substantially from its 52-week peak of $93.61 per share.

✨ Limited Time Offer